Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer

  • Authors:
    • Masako Nakamura
    • Atsushi Takano
    • Phung Manh Thang
    • Bayarbat Tsevegjav
    • Ming Zhu
    • Tomoyuki Yokose
    • Toshinari Yamashita
    • Yohei Miyagi
    • Yataro Daigo
  • View Affiliations

  • Published online on: May 7, 2020     https://doi.org/10.3892/ijo.2020.5060
  • Pages: 277-288
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to identify novel prognostic biomarkers and therapeutic targets for breast cancer; thus, genes that are frequently overexpressed in several types of breast cancer were screened. Kinesin family member 20A (KIF20A) was identified as a candidate molecule during this process. Immunohistochemical staining performed using tissue microarrays from 257 samples of different breast cancer subtypes revealed that KIF20A was expressed in 195 (75.9%) of these samples, whereas it was seldom expressed in normal breast tissue. KIF20A protein was expressed in all types of breast cancer observed. However, it was more frequently expressed in human epidermal growth factor receptor 2 (HER2)‑positive and triple‑negative breast cancer than in the luminal type. Moreover, KIF20A expression was significantly associated with the poor prognosis of patients with breast cancer. A multivariate analysis indicated that KIF20A expression was an independent prognostic factor for patients with breast cancer. The suppression of endogenous KIF20A expression using small interfering ribonucleic acids or via treatment with paprotrain, a selective inhibitor of KIF20A, significantly inhibited breast cancer cell growth through cell cycle arrest at the G2/M phase and subsequent mitotic cell death. These results suggest that KIF20A is a candidate prognostic biomarker and therapeutic target for different types of breast cancer.
View Figures
View References

Related Articles

Journal Cover

July-2020
Volume 57 Issue 1

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Nakamura M, Takano A, Thang PM, Tsevegjav B, Zhu M, Yokose T, Yamashita T, Miyagi Y and Daigo Y: Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. Int J Oncol 57: 277-288, 2020
APA
Nakamura, M., Takano, A., Thang, P.M., Tsevegjav, B., Zhu, M., Yokose, T. ... Daigo, Y. (2020). Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer. International Journal of Oncology, 57, 277-288. https://doi.org/10.3892/ijo.2020.5060
MLA
Nakamura, M., Takano, A., Thang, P. M., Tsevegjav, B., Zhu, M., Yokose, T., Yamashita, T., Miyagi, Y., Daigo, Y."Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer". International Journal of Oncology 57.1 (2020): 277-288.
Chicago
Nakamura, M., Takano, A., Thang, P. M., Tsevegjav, B., Zhu, M., Yokose, T., Yamashita, T., Miyagi, Y., Daigo, Y."Characterization of KIF20A as a prognostic biomarker and therapeutic target for different subtypes of breast cancer". International Journal of Oncology 57, no. 1 (2020): 277-288. https://doi.org/10.3892/ijo.2020.5060